---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-022891"
form_type: "8-K"
ticker: "AIM"
cik: "0000946644"
company_name: "AIM ImmunoTech Inc."
filed_at: "2026-05-14T12:45:38+00:00"
generated_at: "2026-05-14T12:50:38.658955+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AIM ImmunoTech reports Ampligen pancreatic cancer data: OS improvement 7.2 months vs historical controls

## Summary
- Named Patient Program shows PFS 12.6 months (+4 mo) and OS 19.7 months (+7.2 mo) vs historical controls.
- DURIPANC Phase 2 with AstraZeneca's Imfinzi interim data suggests improved QoL; mid-2026 report due June.
- Stratified by Neutrophil/Lymphocyte ratio <4.5: PFS 17.7 months (+9.1 mo) and OS 34.8 months (+22.3 mo).
- CA 19-9 <1000 subgroup: PFS 13.1 months (+4.5 mo) and OS 24.1 months (+11.6 mo).

## SEC filing metadata
- accession: 0001493152-26-022891
- form_type: 8-K
- ticker: AIM
- cik: 0000946644
- company_name: AIM ImmunoTech Inc.
- filed_at: 2026-05-14T12:45:38+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946644/000149315226022891/0001493152-26-022891-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946644/000149315226022891/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-022891
- JSON: https://secwatch.observer/filing/0001493152-26-022891.json
- Plain text: https://secwatch.observer/filing/0001493152-26-022891.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.